Piperacillin/tazobactam in Treatment of Hospital Acquired Pneumonia in Intensive Care Unit

OBJECTIVE To study the clinical effect of piperacillin/tazobactam in the treatment of hospital (acquired) pneumonia in intensive care unit. METHODS Sixty four cases of hospital acquired pneumonia were (randomly) divided into piperacillin/tazobactam treatment group ((32 cases) )and ceftazidime treatment group ((32 cases).) The therapeutic effect and safety were compared between the two groups. RESULTS The effective rate, bacteria eradication rate and bacteria sensitivity rate were 93.8%, 87.8% and 83.3%, respectively in piperacillin/tazobactam group, while the counterpart indexes were 81.3%, 75.6% and 79.5%, respectively in ceftazidime group. The effective rate and bacteria eradication rate in piperacillin/tazobactam treatment group were higher than in ceftazidime one (P0.05), but there was no significant difference in bacteria sensitivity rate between the two groups (P0.05). Both two groups had transient and slight side effects. (CONCLUSIONS )Piperacillin/tazobactam is a safe and effective oral antibiotic for treatment of hospital acquired pneumonia.